Skip to content
value.today
Cyclerion Therapeutics, Inc. logo

Cyclerion Therapeutics, Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2018
Total raised
$199 M
2 rounds on record
Latest round
$24 M
Jul 2020
First round on record
Apr 2019
Today
Went public
See the company page

Cyclerion Therapeutics, Inc. is listed today as Korsana Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cyclerion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$5 MPrivate placement after listing$2 to $10 million

Cyclerion Therapeutics, Inc.: Private sale, May 2023

Investors in this round

1 investor had bought by the notice of May 25, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Cyclerion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Anjeza M. Gjino · Executive Officer
  • Cheryl M. Gault · Executive Officer
  • Peter M. Hecht · Director, Executive Officer
  • Errol M. De Souza · Director
  • Ole M. Isacson · Director
  • Steven M. Hyman · Director
  • Terrance M. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Anjeza Gjino, Chief Financial Officer. Source: SEC Form D, newest notice filed May 25, 2023. Read the notice at the SEC.

equitySEC
Jun 2021$18 MPrivate placement after listing$10 to $50 million

Cyclerion Therapeutics, Inc.: Private sale, Jun 2021

Investors in this round

7 investors had bought by the notice of Jun 17, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Cyclerion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Andreas M. Busch · Executive Officer
  • Anjeza M. Gjino · Executive Officer
  • Cheryl M. Gault · Executive Officer
  • Peter M. Hecht · Executive Officer, Director
  • Errol M. De Souza · Director
  • George M. Conrades · Director
  • Kevin M. Churchwell · Director
  • Marsha M. Fanucci · Director
  • Michael M. Mendelsohn · Director
  • Ole M. Isacson · Director
  • Stephanie M. Lovell · Director
  • Terrance M. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Anjeza Gjino, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 17, 2021. Read the notice at the SEC.

equitySEC
Jul 2020$24 MNo. 2$10 to $50 million

Cyclerion Therapeutics, Inc.: Raise no. 2, Jul 2020

Investors in this round

2 investors had bought by the notice of Aug 11, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Cyclerion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Andreas E. Busch · Executive Officer
  • Mark G. Currie · Executive Officer
  • Peter M. Hecht · Executive Officer, Director
  • William G. Huyett · Executive Officer
  • Amy E. Schulman · Director
  • George E. Conrades · Director
  • Kevin E. Churchwell · Director
  • Marsha E. Fanucci · Director
  • Michael E. Mendelsohn · Director
  • Ole E. Isacson · Director
  • Stephanie E. Lovell · Director
  • Terrance E. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Huyett, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 11, 2020. Read the notice at the SEC.

equitySEC
Apr 2019$175 MNo. 1$50 to $250 million

Cyclerion Therapeutics, Inc.: Raise no. 1, Apr 2019

Investors in this round

49 investors had bought by the notice of Apr 17, 2019: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Cyclerion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$175 M of $175 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$10,150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Mark G. Currie · Executive Officer
  • Peter M. Hecht · Executive Officer, Director
  • William G. Huyett · Executive Officer
  • Amy G. Schulman · Director
  • George G. Conrades · Director
  • Kevin G. Churchwell · Director
  • Marsha G. Fanucci · Director
  • Michael G. Mendelsohn · Director
  • Ole G. Isacson · Director
  • Stephanie G. Lovell · Director
  • Terrance G. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • J.P. Morgan Securities LLC (CRD 79) · New York, New YorkSold in CA, CT, FL, MA, MD, ME, NY, OH, TN
  • Credit Suisse Securities (USA) LLC (CRD 816) · New York, New YorkSold in CA, CT, FL, MA, MD, ME, NY, OH, TN

Signed by William Huyett, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cyclerion Therapeutics, Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (May 2023).

    SEC Form D (revenue range) · May 2023

  • Revenue range over time, as stated in its notices: no revenue in 2019; revenue between $1 million and $5 million in 2020; revenue between $1 million and $5 million in 2021; revenue between $1 million and $5 million in 2023.

    SEC Form D (revenue range) · May 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2023

Products and services#

No products or services of Cyclerion Therapeutics, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Cyclerion Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Fairmount Funds Management LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
Fairmount Healthcare Co-Invest VI L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3
Fairmount Healthcare Fund II L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 49 investors.

Largest shareholders today

Institutions holding Korsana Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cyclerion Therapeutics, Inc.
NameRoleNamed in
Anjeza M. GjinoExecutive officerMay 2023
Cheryl M. GaultExecutive officerMay 2023
Peter M. HechtExecutive officerMay 2023
Andreas M. BuschExecutive officerJun 2021
Andreas E. BuschExecutive officerAug 2020
Mark G. CurrieExecutive officerAug 2020
William G. HuyettExecutive officerAug 2020
Errol M. De SouzaDirectorMay 2023
Ole M. IsacsonDirectorMay 2023
Peter M. HechtDirectorMay 2023
Steven M. HymanDirectorMay 2023
Terrance M. McGuireDirectorMay 2023
George M. ConradesDirectorJun 2021
Kevin M. ChurchwellDirectorJun 2021
Marsha M. FanucciDirectorJun 2021
Michael M. MendelsohnDirectorJun 2021
Stephanie M. LovellDirectorJun 2021
Amy E. SchulmanDirectorAug 2020
George E. ConradesDirectorAug 2020
Kevin E. ChurchwellDirectorAug 2020
Marsha E. FanucciDirectorAug 2020
Michael E. MendelsohnDirectorAug 2020
Ole E. IsacsonDirectorAug 2020
Stephanie E. LovellDirectorAug 2020
Terrance E. McGuireDirectorAug 2020
Amy G. SchulmanDirectorApr 2019
George G. ConradesDirectorApr 2019
Kevin G. ChurchwellDirectorApr 2019
Marsha G. FanucciDirectorApr 2019
Michael G. MendelsohnDirectorApr 2019
Ole G. IsacsonDirectorApr 2019
Stephanie G. LovellDirectorApr 2019
Terrance G. McGuireDirectorApr 2019

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.